| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
|
N Engl J Med
|
2004
|
32.09
|
|
2
|
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
|
J Clin Oncol
|
2008
|
18.54
|
|
3
|
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
|
N Engl J Med
|
2014
|
12.29
|
|
4
|
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
|
Nat Med
|
2009
|
6.61
|
|
5
|
Contemporary role of androgen deprivation therapy for prostate cancer.
|
Eur Urol
|
2011
|
2.68
|
|
6
|
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
|
BJU Int
|
2011
|
2.68
|
|
7
|
Bladder cancer.
|
J Natl Compr Canc Netw
|
2013
|
2.46
|
|
8
|
Expanding treatment options for metastatic prostate cancer.
|
N Engl J Med
|
2011
|
2.39
|
|
9
|
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.
|
J Nucl Med
|
2012
|
2.00
|
|
10
|
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
|
Mol Imaging Biol
|
2015
|
1.90
|
|
11
|
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
|
Eur J Cancer
|
2012
|
1.87
|
|
12
|
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
|
Eur J Cancer
|
2011
|
1.80
|
|
13
|
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
|
J Urol
|
2007
|
1.75
|
|
14
|
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
|
J Clin Oncol
|
2011
|
1.75
|
|
15
|
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
|
Cancer
|
2008
|
1.73
|
|
16
|
Clinical practice. Localized prostate cancer.
|
N Engl J Med
|
2007
|
1.72
|
|
17
|
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
|
J Clin Oncol
|
2008
|
1.71
|
|
18
|
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).
|
J Urol
|
2012
|
1.65
|
|
19
|
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.
|
Eur Urol
|
2011
|
1.64
|
|
20
|
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.
|
Eur Urol
|
2011
|
1.62
|
|
21
|
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.
|
Prostate
|
2011
|
1.58
|
|
22
|
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
|
Cancer
|
2011
|
1.55
|
|
23
|
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
|
Prostate
|
2013
|
1.52
|
|
24
|
Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
|
Clin Cancer Res
|
2005
|
1.46
|
|
25
|
Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.
|
Cancer
|
2012
|
1.33
|
|
26
|
Bladder cancer.
|
J Natl Compr Canc Netw
|
2009
|
1.32
|
|
27
|
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
|
Urol Oncol
|
2010
|
1.31
|
|
28
|
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
|
Clin Cancer Res
|
2005
|
1.30
|
|
29
|
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.
|
Cancer
|
2012
|
1.28
|
|
30
|
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
|
J Clin Oncol
|
2002
|
1.27
|
|
31
|
Cancer-related fatigue.
|
J Natl Compr Canc Netw
|
2010
|
1.26
|
|
32
|
Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
|
J Urol
|
2007
|
1.22
|
|
33
|
Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.
|
BJU Int
|
2010
|
1.20
|
|
34
|
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination.
|
Eur J Cancer
|
2011
|
1.20
|
|
35
|
Cancer-related fatigue. Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2007
|
1.10
|
|
36
|
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.
|
J Urol
|
2007
|
1.10
|
|
37
|
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
|
Cancer
|
2002
|
1.08
|
|
38
|
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
|
Eur Urol
|
2013
|
1.07
|
|
39
|
Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.
|
J Clin Oncol
|
2007
|
1.05
|
|
40
|
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.
|
Cancer
|
2013
|
1.05
|
|
41
|
Novel targeted therapeutics for metastatic castration-resistant prostate cancer.
|
Cancer Lett
|
2009
|
1.04
|
|
42
|
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.
|
Oncologist
|
2012
|
1.04
|
|
43
|
Bladder cancer. Clinical guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
1.04
|
|
44
|
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
|
Am J Clin Oncol
|
2006
|
1.01
|
|
45
|
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.
|
BJU Int
|
2012
|
1.00
|
|
46
|
CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.
|
J Urol
|
2008
|
1.00
|
|
47
|
Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
|
J Clin Oncol
|
2003
|
1.00
|
|
48
|
Cancer-Related Fatigue, Version 2.2015.
|
J Natl Compr Canc Netw
|
2015
|
1.00
|
|
49
|
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
|
Clin Cancer Res
|
2005
|
1.00
|
|
50
|
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.
|
Oncologist
|
2013
|
0.99
|
|
51
|
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
|
Urology
|
2007
|
0.97
|
|
52
|
Penile cancer: Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2013
|
0.97
|
|
53
|
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.
|
Cancer Chemother Pharmacol
|
2011
|
0.96
|
|
54
|
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.
|
Clin Cancer Res
|
2010
|
0.95
|
|
55
|
Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations.
|
J Natl Compr Canc Netw
|
2004
|
0.93
|
|
56
|
Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
|
Urol Oncol
|
2009
|
0.92
|
|
57
|
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
|
Prostate
|
2014
|
0.92
|
|
58
|
Management of patients with biochemical recurrence after local therapy for prostate cancer.
|
Hematol Oncol Clin North Am
|
2013
|
0.92
|
|
59
|
Bladder cancer. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2005
|
0.91
|
|
60
|
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
|
Cancer
|
2014
|
0.90
|
|
61
|
Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
|
Nat Clin Pract Oncol
|
2008
|
0.88
|
|
62
|
Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.
|
J Clin Oncol
|
2013
|
0.87
|
|
63
|
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.
|
Prostate
|
2011
|
0.84
|
|
64
|
AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy.
|
Prostate
|
2011
|
0.83
|
|
65
|
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
|
Cancer Biol Ther
|
2007
|
0.81
|
|
66
|
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
|
Prostate
|
2011
|
0.81
|
|
67
|
The dilemma of patients with a rising PSA level after definitive local therapy for prostate cancer.
|
Semin Urol Oncol
|
2002
|
0.78
|
|
68
|
LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy?
|
Oncology (Williston Park)
|
2009
|
0.76
|
|
69
|
A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy.
|
Rev Urol
|
2003
|
0.75
|
|
70
|
Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease.
|
BJU Int
|
2008
|
0.75
|
|
71
|
Treat early or wait? A stubborn question that remains unanswered.
|
Eur Urol
|
2008
|
0.75
|
|
72
|
A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy.
|
Rev Urol
|
2003
|
0.75
|
|
73
|
Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?
|
Nat Clin Pract Urol
|
2008
|
0.75
|
|
74
|
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
|
Cancer Chemother Pharmacol
|
2010
|
0.75
|
|
75
|
Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference.
|
J Urol
|
2007
|
0.75
|